Clarithromycin (Klamer 500 mg) and Rimegepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A4 inhibition can substantially increase rimegepant exposure.
Clinical significance and safety
Rimegepant should not be combined with Clarithromycin, because its clarithromycin component inhibits CYP3A4 and can increase rimegepant exposure. The rimegepant label advises avoiding strong CYP3A4 inhibitors; a prescriber should review an alternative before either medicine is used together.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.